Valvular heart disease associated with fenfluramine-phentermine
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Fenfluramine and phentermine have been individually approved as anorectic agents by the Food and Drug Administration (FDA). When used in combination the drugs may be just as effective as either drug alone, with the added advantages of the need for lower doses of each agent and perhaps fewer side effects. Although the combination has not been approved by the FDA, in 1996 the total number of prescriptions in the United States for fenfluramine and phentermine exceeded 18 million. METHODS: We identified valvular heart disease in 24 women treated with fenfluramine-phentermine who had no history of cardiac disease. The women presented with cardiovascular symptoms or a heart murmur. As increasing numbers of these patients with similar clinical features were identified, there appeared to be an association between these features and fenfluramine-phentermine therapy. RESULTS: Twenty-four women (mean [+/-SD] age, 44+/-8 years) were evaluated 12.3+/-7.1 months after the initiation of fenfluramine-phentermine therapy. Echocardiography demonstrated unusual valvular morphology and regurgitation in all patients. Both right-sided and left-sided heart valves were involved. Eight women also had newly documented pulmonary hypertension. To date, cardiac surgical intervention has been required in five patients. The heart valves had a glistening white appearance. Histopathological findings included plaque-like encasement of the leaflets and chordal structures with intact valve architecture. The histopathological features were identical to those seen in carcinoid or ergotamine-induced valve disease. CONCLUSIONS: These cases arouse concern that fenfluramine-phentermine therapy may be associated with valvular heart disease. Candidates for fenfluramine-phentermine therapy should be informed about serious potential adverse effects, including pulmonary hypertension and valvular heart disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Early weight loss medications, such as fenfluramine (Fen-Phen) and sibutramine, were withdrawn due to severe cardiovascular and psychiatric side effects [3,4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“While effective (average 10–15% weight loss), fenfluramine was withdrawn in 1997 after studies linked it to valvular heart disease and pulmonary hypertension [3].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“While effective (average 10–15% weight loss), fenfluramine was withdrawn in 1997 after studies linked it to valvular heart disease and pulmonary hypertension [3].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“Certainly, starvation, very-low-calorie diets, liquid protein diets, and obesity surgeries have been associated with prolongation of the QTc interval and increased risk of malignant dysrhythmias (1), and various pharmacologic agents have either limited efficacy or considerable toxicity (70 -72).”
From Obesity and Cardiovascular Disease (2009) · cites this paper as [70]
Citations
Cites
Appetite-suppressant drugs and the risk of primary pulmonary hypertension
Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350901 · Cited by 1,162
Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.
Pellikka, P. A., Tajik, A. J., Khandheria, B. K., Seward, J. B., Callahan, J. A., Pitot, H. C., & Kvols, L. K. (1993) · Circulation · doi:10.1161/01.cir.87.4.1188 · Cited by 614
Robiolio, P. A., Rigolin, V. H., Wilson, J. S., Harrison, J. K., Sanders, L. L., Bashore, T. M., & Feldman, J. M. (1995) · Circulation · doi:10.1161/01.cir.92.4.790 · Cited by 406
Doppler Echocardiography: Theory, Instrumentation, Technique, and Application
NISHIMURA, R. A., MILLER, F. A., CALLAHAN, M. J., BENASSI, R. C., SEWARD, J. B., & TAJIK, A. J. (1985) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60540-0 · Cited by 263
Primary pulmonary hypertension and fenfluramine use.
Brenot, F., Herve, P., Petitpretz, P., Parent, F., Duroux, P., & Simonneau, G. (1993) · Heart · doi:10.1136/hrt.70.6.537 · Cited by 251
Weir, E. K., Reeve, H. L., Huang, J. M. C., Michelakis, E., Nelson, D. P., Hampl, V., & Archer, S. L. (1996) · Circulation · doi:10.1161/01.cir.94.9.2216 · Cited by 218
Klein, A. L., Burstow, D. J., Tajik, A. J., Zachariah, P. K., Taliercio, C. P., Taylor, C. L., Bailey, K. R., & Seward, J. B. (1990) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(14)80299-x · Cited by 213
Valve Disease Associated with Ergot Alkaloid Use: Echocardiographic and Pathologic Correlations
Redfield, M. M., Nicholson, W. J., Edwards, W. D., & Tajik, A. J. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-50 · Cited by 156
Self-citationHormonal responses to fenfluramine in depressed and control subjects
Mitchell, P. B., & Smythe, G. A. (1990) · Journal of Affective Disorders · doi:10.1016/0165-0327(90)90008-v · Cited by 99
Irreversible pulmonary hypertension after treatment with fenfluramine.
McMurray, J. J. V., Bloomfield, P. M., & Miller, H. (1986) · BMJ · doi:10.1136/bmj.292.6515.239-a · Cited by 50
Research works printed but not linked: 4
- Heuer L, 1978, Chir Prax, 23, 497
- Tajik AJ, 1978, Mayo Clin Proc, 53, 271
- Thorson AH, 1958, Acta Med Scand Suppl, 334, 99
- Morita T, 1983, Am Rev Respir Dis, 127, 747
Cited by
Items 501–600 of 1,001
Polster, T. (2018) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2018.08.021 · Cited by 44
“When fenfluramine was used in adults with obesity, it was associatedwith an increased risk of primary pulmonary hypertension and cardiac valvulopathy [25,26].”
Risks associated with fat burners: A toxicological perspective
Jakopin, Ž. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.10.051 · Cited by 49
Emerging Concepts in the Medical and Surgical Treatment of Obesity
Aylwin, S., & Al-Zaman, Y. (2008) · Frontiers of Hormone Research · doi:10.1159/000115368 · Cited by 41
Definition and Classification of Pulmonary Hypertension
Humbert, M. J. C., Montani, D., Evgenov, O. V., & Simonneau, G. (2013) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-38664-0_1 · Cited by 47
Preclinical Cardiac Safety Assessment??of Drugs
Hanton, G. C. (2007) · Drugs in R&D · doi:10.2165/00126839-200708040-00002 · Cited by 43
Serotonergic pathways converge upon central melanocortin systems to regulate energy balance
Zhou, L., Williams, T. B., Lachey, J. L., Kishi, T., Cowley, M. A., & Heisler, L. K. (2005) · Peptides · doi:10.1016/j.peptides.2004.12.028 · Cited by 43
The Assault on the Swan-Ganz Catheter
Weil, M. H. (1998) · CHEST Journal · doi:10.1378/chest.113.5.1379 · Cited by 41
Eddahibi, S., Adnot, S., Frisdal, É., Levame, M., Hamon, M., & Raffestin, B. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29522-7 · Cited by 41
The future of obesity research
Greenway, F. L., & Smith, S. R. (2000) · Nutrition · doi:10.1016/s0899-9007(00)00406-8 · Cited by 53
Stummann, T. C., Beilmann, M., Duker, G., Dumotier, B. M., Fredriksson, J. M., Jones, R. L., Hasiwa, M., Kang, Y. J., Mandenius, C., Meyer, T. S., et al. (2009) · Cardiovascular Toxicology · doi:10.1007/s12012-009-9045-3 · Cited by 41
Risk of valvular heart disease associated with use of fenfluramine
Hopkins, P. N., & Polukoff, G. I. (2003) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-3-5 · Cited by 41
Tazarotene gel: Efficacy and safety in plaque psoriasis
Weinstein, G. D. (1997) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(97)80398-2 · Cited by 40
Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease
Bays, H. E. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.123 · Cited by 39
Identification of Alverine and Benfluorex as HNF4α Activators
Lee, S., Athavankar, S., Cohen, T., Piran, R., Kiselyuk, A., & Levine, F. (2013) · ACS Chemical Biology · doi:10.1021/cb4000986 · Cited by 39
Shu, Q., Chen, L., Wu, S., Li, J., Liu, J., Xiao, L., Chen, R., & Liang, F.-X. (2020) · Obesity Facts · doi:10.1159/000503752 · Cited by 44
Drug-Induced Cardiovascular Disorders
Murphy, C. A., & Dargie, H. J. (2007) · Drug Safety · doi:10.2165/00002018-200730090-00005 · Cited by 40
Bond, L. M., & Ntambi, J. M. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m078469 · Cited by 40
Disatian, S., Lacerda, C. M. R., & Orton, E. C. (2010) · PubMed · Cited by 39
Pharmacologic Treatment of Autism
Palermo, M. T., & Curatolo, P. (2004) · Journal of Child Neurology · doi:10.1177/088307380401900301.155 · Cited by 39
Histologic Changes in Three Explanted Native Cardiac Valves Following Use of Fenfluramines
Steffee, C. H., Singh, H. K., & Chitwood, W. R. (1999) · Cardiovascular Pathology · doi:10.1016/s1054-8807(99)00019-8 · Cited by 39
Valvular Heart Disease Associated with Fenfluramine–Phentermine
Rasmussen, S., Corya, B. C., & Glassman, R. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712113372414 · Cited by 39
Ullah, M. I., & Tamanna, S. (2025) · Medicines · doi:10.3390/medicines12030019 · Cited by 38
Combination phentermine and topiramate extended release in the management of obesity.
Alfaris, N., Minnick, A. M., Hopkins, C. M., Berkowitz, R. I., & Wadden, T. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1041505 · Cited by 38
Tribouilloy, C. M., Ruşinaru, D., Maréchaux, S., Jeu, A., Éderhy, S., Donal, E., Réant, P., Arnalsteen, E., Boulanger, J., Ennezat, P., et al. (2012) · Circulation · doi:10.1161/circulationaha.112.111260 · Cited by 38
Current trends and future prospects of lipstatin: a lipase inhibitor and pro-drug for obesity
Kumar, P., & Dubey, K. K. (2015) · RSC Advances · doi:10.1039/c5ra14892h · Cited by 40
Combination therapy for obesity
Wilding, J. P. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117737401 · Cited by 37
Interbreed variation in serum serotonin (5-hydroxytryptamine) concentration in healthy dogs
Höglund, K., Häggström, J. U., Hanås, S., Merveille, A., Gouni, V., Wiberg, M. E., Willesen, J. L., Entee, K. M., Sørensen, L. M., Tiret, L., et al. (2018) · Journal of Veterinary Cardiology · doi:10.1016/j.jvc.2018.05.002 · Cited by 39
“In people receiving oral serotonergic medication, cardiac valvulopathy has been observed [19,20], and in animal models, rats injected with 5-HT developed myxomatous-like valvular changes [21,22].”
BackgroundFishbein, G. A., & Fishbein, M. C. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1145-5 · Cited by 38
Development of Capsaicin Loaded Nanoparticles Based Microneedle Patch for Transdermal Drug Delivery
Mudhol, S., & Peddha, M. S. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.104120 · Cited by 40
Combinations of drugs in the Treatment of Obesity
Halpern, B., Oliveira, E. S. L., Faria, A. M., Halpern, A., Melo, M. E. D., Cercato, C., & Mancini, M. C. (2010) · Pharmaceuticals · doi:10.3390/ph3082398 · Cited by 35
Hong, Z., Smith, A. J., Archer, S. L., Wu, X.-C., Nelson, D. P., Peterson, D. A., Johnson, G. J., & Weir, Ε. K. (2005) · Circulation · doi:10.1161/circulationaha.105.556704 · Cited by 41
Cardiovascular Effects of Noncardiovascular Drugs
Raj, S. R., Stein, C. M., Saavedra, P. J., & Roden, D. M. (2009) · Circulation · doi:10.1161/circulationaha.107.728576 · Cited by 41
The Case for Medical Management of Obesity: A Call for Increased Physician Involvement
Rippe, J. M. (1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00685.x · Cited by 37
Lepor, N. E., Gross, S. B., Daley, W. L., Samuels, B. A., Rizzo, M. J., Luko, S. P., Hickey, A., Buchbinder, N. A., & Naqvi, T. Z. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)00840-7 · Cited by 38
Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists
Orcholski, M. E., Yuan, K., Rajasingh, C. M., Tsai, H., Shamskhou, E. A., Dhillon, N. K., Voelkel, N. F., Zamanian, R. T., & Pérez, V. D. J. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00553.2017 · Cited by 40
“During this same time, evidence mounted that fenfluramine and its relatives were associated with cardiac valvular lesions (23).”
BackgroundCurrent Treatment Strategies and Future Treatment Options for Dravet Syndrome
Ziobro, J. M., Eschbach, K. L., Sullivan, J. E., & Knupp, K. G. (2018) · Current Treatment Options in Neurology · doi:10.1007/s11940-018-0537-y · Cited by 40
Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists
Sandsdal, R. M., Juhl, C. R., & Torekov, S. S. (2019) · Drug Safety · doi:10.1007/s40264-019-00812-7 · Cited by 40
Evaluation of Selective 5-HT 2C Agonists in Acute Seizure Models
Silenieks, L. B., Carroll, N. K., Niekerk, A. V., Niekerk, E. V., Taylor, C., Upton, N., & Higgins, G. A. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00739 · Cited by 41
Risks associated with herbal slimming remedies
Corns, C. M., & Metcalfe, K. (2002) · The Journal of the Royal Society for the Promotion of Health · doi:10.1177/146642400212200407 · Cited by 37
Brown Adipose Tissue Blood Flow and Mass in Obesity: A Contrast Ultrasound Study in Mice
Clerté, M., Baron, D. M., Brouckaert, P., Ernande, L., Raher, M. J., Flynn, A. W., Picard, M. H., Bloch, K. D., Buys, E. S., & Scherrer‐Crosbie, M. (2013) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2013.07.015 · Cited by 38
Activin A in Carcinoid Heart Disease: A Possible Role in Diagnosis and Pathogenesis
Bergestuen, D. S., Edvardsen, T., Aakhus, S., Ueland, T., Øie, E., Vatn, M., Aukrust, P., & Thiis‐Evensen, E. (2010) · Neuroendocrinology · doi:10.1159/000318014 · Cited by 37
Combination Drugs for Treating Obesity
Greenway, F. L., & Bray, G. A. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0096-4 · Cited by 41
“The 2B receptors are on the heart valves, and fenfluramine was removed from the market because of cardiac valvulopathy [ 20 ].”
BackgroundThe frequency of cardiac valvular regurgitation in Parkinson's disease
Yamashiro, K., Komine‐Kobayashi, M., Hatano, T., Urabe, T., Mochizuki, H., Hattori, N., Iwama, Y., Daida, H., Sakai, M., Nakayama, T., et al. (2008) · Movement Disorders · doi:10.1002/mds.22036 · Cited by 38
da Cunha, L. D. C. B. P., da Cunha, C. L. P., de Souza, A. M., Neto, N. C., Pereira, R. S., & Suplicy, H. L. (2006) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2006001800011 · Cited by 49
Effective Diet and Exercise Treatments for Overweight and Recommendations for Intervention
Miller, W. C. (2001) · Sports Medicine · doi:10.2165/00007256-200131100-00002 · Cited by 47
Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels
Bělohlávková, S., Šimák, J., Kokešová, A., Hniličková, O., & Hampl, V. (2001) · Journal of Applied Physiology · doi:10.1152/jappl.2001.91.2.755 · Cited by 37
“THE PROMISING POTENTIAL of DL-fenfluramine (and its active stereoisomer, D-fenfluramine or dexfenfluramine) as a weight-reducing treatment (5, 26) has been halted by the finding that it substantially increases the risk of severe pulmonary hypertension (1, 6) and valvular heart lesions (7, 14).”
BackgroundHigh incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium
Delcroix, M., Kurz, X., Walckiers, D., DEMEDTS, M. G., & Naeije, R. (1998) · European Respiratory Journal · doi:10.1183/09031936.98.12020271 · Cited by 37
Serotonin contribution to cardiac valve degeneration: new insights for novel therapies?
Ayme‐Dietrich, E., Lawson, R., Silva, S. D., Mazzucotelli, J. P., & Monassier, L. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.009 · Cited by 41
No clinically significant valvular regurgitation in long‐term cabergoline treatment for prolactinoma
Halperín, I., Aller, J., Varela, C., Mora, M., Abad, A. Z., Doltra, A., Santos, A. E., Batista, E., García‐Pavía, P., Sitges, M., et al. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04349.x · Cited by 38
Droogmans, S., Roosens, B., Cosyns, B., Degaillier, C., Hernot, S., Weytjens, C., Garbar, C., Caveliers, V., Pipeleers-Marichal, M. A., Franken, P. R., et al. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01177.2008 · Cited by 37
“SEVERAL DRUGS, such as ergotamine, methysergide, fenfluramine, pergolide, and cabergoline, have been associated with valvular heart disease (1, 22, 26, 31, 34).”
Modern Obesity Pharmacotherapy: Weighing Cardiovascular Risk and Benefit
Cunningham, J. W., & Wiviott, S. D. (2014) · Clinical Cardiology · doi:10.1002/clc.22304 · Cited by 37
Ven, F. L., Tribouilloy, C., Habib, G., Gueffet, J.-P., Maréchaux, S., Eicher, J., Blanchard-Lemoine, B., Rousseau, J., Henon, P., Jobic, Y., et al. (2010) · European Journal of Echocardiography · doi:10.1093/ejechocard/jeq172 · Cited by 37
Mechanotransduction Mechanisms in Mitral Valve Physiology and Disease Pathogenesis
Pagnozzi, L. A., & Butcher, J. T. (2017) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2017.00083 · Cited by 36
Barrea, L., Pugliese, G., Muscogiuri, G., Laudisio, D., Colao, A. A. L., & Savastano, S. (2020) · Minerva Endocrinology · doi:10.23736/s0391-1977.20.03179-x · Cited by 38
Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta‐analyses
Sposito, A. C., Bonilha, I., Luchiari, B., Benchimol, A. K., Hohl, A., Moura, F., Cercato, C., Geloneze, B., Nadruz, W., Aguilar-Salinas, C. A., et al. (2021) · Obesity Reviews · doi:10.1111/obr.13224 · Cited by 36
Rasmussen, V. G., Østergaard, K., Dupont, E., & Poulsen, S. H. (2011) · Movement Disorders · doi:10.1002/mds.23470 · Cited by 39
Rooney, J. S., McDowell, A., Strachan, C. J., & Gordon, K. C. (2015) · Talanta · doi:10.1016/j.talanta.2015.02.016 · Cited by 35
Switching and combining dopamine agonists
Reichmann, H., Herting, B., M�ller, A., & Sommer, U. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-003-0081-z · Cited by 35
Kancherla, M. K., Salti, H. I., Mulderink, T. A., Parker, M. A., Bonow, R. O., & Mehlman, D. J. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00567-6 · Cited by 35
Valvulopatía cardíaca asociada al uso de benfluorex
Rafel, J., Casañas, R., Anguera, N., n, N. B. S. U., Cels, A. C., & Capmany, R. P. (2003) · Revista Española de Cardiología · doi:10.1016/s0300-8932(03)76849-3 · Cited by 35
Actions of amphetamine derivatives and cathinone at the noradrenaline transporter.
Cleary, L., & Docherty, J. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)02173-3 · Cited by 37
Cardiac Valve Regurgitation With Pergolide Compared With Nonergot Agonists in Parkinson Disease
Dewey, R. B., Reimold, S. C., & O’Suilleabhain, P. E. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.377 · Cited by 35
“This induction of valve regurgitation is plausibly related to the stimulation of serotonin receptors by pergolide,(9) a feature it shares with fenfluramine hydrochloride,(10) a drug associated with valvulopathy.(11) Although we have shown that pergolide is associated with more valve regurgitation than the nonergot dop…”
BackgroundSchiller, R. N., Barrager, E., Schauss, A. G., & Nichols, E. J. (2001) · Cited by 50
What Is Carcinoid Syndrome? A Critical Appraisal of Its Proposed Mediators
Mulders, M. C. F., de Herder, W. W., & Hofland, J. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad035 · Cited by 36
“Weighing in” on synergy: Preclinical research on neurohormonal anti-obesity combinations
Roth, J. D., Trevaskis, J. L., Turek, V. F., & Parkes, D. G. (2010) · Brain Research · doi:10.1016/j.brainres.2010.01.027 · Cited by 37
“The “fen/ phen” combination demonstrated impressive weight loss efficacy (Weintraub et al., 1992) until cardio-safety concerns linked to fenfluramine led to its withdrawal from the market (Connolly et al., 1997).”
BackgroundNew Pharmacological Treatments for the Management of Obesity
Hurt, R. T., Varayil, J. E., & Ebbert, J. O. (2014) · Current Gastroenterology Reports · doi:10.1007/s11894-014-0394-0 · Cited by 39
Role of impulsivity and reward in the anti-obesity actions of 5-HT 2C receptor agonists
Higgins, G. A., Zeeb, F. D., & Fletcher, P. J. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117735797 · Cited by 34
“Despite its clinical efficacy, (dex)fenfluramine was withdrawn from the market in 1997 due to cardiac valvulopathy and pulmonary hypertension (Connolly et al., 1997).”
BackgroundPulmonary Arterial Hypertension: Yesterday, Today, Tomorrow
Michelakis, E. D. (2014) · Circulation Research · doi:10.1161/circresaha.115.301132 · Cited by 36
Obesity an overview: Genetic conditions and recent developments in therapeutic interventions
Rao, V., Candasamy, M., & Bhattamisra, S. K. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.05.004 · Cited by 39
CNS-targeting pharmacological interventions for the metabolic syndrome
Stemmer, K., Müller, T. D., DiMarchi, R. D., Pfluger, P. T., & Tschöp, M. H. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129195 · Cited by 36
“Fenfluramine (Pondimin) Serotonin-releasing agent by binding to the serotonin transporter (165, 169) 1964 (France), 1973 (US) 1997 Valvular heart disease and pulmonary hypertension (52), likely as a result of 5-HT2B receptor activation, expressed on cardiac valvular interstitial cells (170)”
BackgroundFenfluramine as antiseizure medication for epilepsy
Γώγου, Μ., & Cross, J. H. (2021) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.14822 · Cited by 36
Conde, K., Fang, S., & Xu, Y. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01091-7 · Cited by 35
Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke
Derby, L. E., Myers, M. W., & Jick, H. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00928.x · Cited by 34
Balachandran, K., Hussain, S., Yap, C.-H., Padala, M., Chester, A. H., & Yoganathan, A. P. (2011) · Cardiovascular Pathology · doi:10.1016/j.carpath.2011.07.005 · Cited by 34
“Our results suggest that this may be due to the increased collagen synthesis leading to thickening and stiffening throughout the cusp resulting in reduced ability of the valve to coapt effectively [6].”
Emerging pharmacological approaches to the treatment of obesity.
Wasan, K. M., & Looije, N. (2005) · PubMed · Cited by 39
Neuronal Regulation of Aortic Valve Cusps
El-Hamamsy, I., Yacoub, M. H., & Chester, A. H. (2009) · Current Vascular Pharmacology · doi:10.2174/157016109787354088 · Cited by 40
“As mentioned earlier, 5-HT receptor activation by the use of 5-HT agonists or dopamine agonists can lead to severe fibrodysplastic changes in heart valves requiring surgical intervention [46, 55, 56].”
BackgroundDexfenfluramine as a mitogen signals through the formation of superoxide anion
Lee, S.-L., Wang, W.-W., & Fanburg, B. L. (2001) · The FASEB Journal · doi:10.1096/fj.00-0431fje · Cited by 34
Kelly, C. R., & Sharif, N. A. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.100172 · Cited by 38
Diet Drug-Related Cardiac Valve Disease: The Mayo Clinic Echocardiographic Laboratory Experience
Teramae, C. Y., Connolly, H. M., Grogan, M. A., & Miller, F. A. (2000) · Mayo Clinic Proceedings · doi:10.4065/75.5.456 · Cited by 34
Self-citationProthrombotic mechanisms in primary pulmonary hypertension
Farber, H. W., & Loscalzo, J. (1999) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(99)90094-x · Cited by 36
The Safety of New Medicines: The Importance of Asking the Right Questions
Wood, A. J. J. (1999) · JAMA · doi:10.1001/jama.281.18.1753 · Cited by 34
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Son, J. W., & Lim, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1940 · Cited by 33
Recent Advances in Pharmacologic Treatments of Drug-Resistant Epilepsy: Breakthrough in Sight
Klein, P., Friedman, D. J., & Kwan, P. (2024) · CNS Drugs · doi:10.1007/s40263-024-01130-y · Cited by 37
Liu, C., Lee, S., & Elmquist, J. K. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.02.008 · Cited by 38
Strom, B. L. (2019) · Pharmacoepidemiology · doi:10.1002/9781119413431.ch1 · Cited by 35
Alger, S. A., Malone, M., Cerulli, J., Fein, S., & Howard, L. (1999) · Obesity Research · doi:10.1002/j.1550-8528.1999.tb00435.x · Cited by 32
Obesity and cardiovascular hemodynamic function
Koch, R., & Sharma, A. M. (1999) · Current Hypertension Reports · doi:10.1007/s11906-999-0006-9 · Cited by 38
“The recent implication of appetite suppressant drugs in the development of cardiac valvular dysfunction [ 4 ] has spawned a number of studies that have focused on the morphology and function of heart valves in obese individuals.”
BackgroundWeight-modification trials in older adults: what should the outcome measure be?
Diehr, P., Newman, A. B., Jackson, S. A., Kuller, L., & Powe, N. (2002) · Current Controlled Trials in Cardiovascular Medicine · doi:10.1186/1468-6708-3-1 · Cited by 34
Cardiovascular Effects of the New Weight Loss Agents
Vorsanger, M., Subramanyam, P., WEINTRAUB, H. S., Lamm, S. H., Underberg, J. A., Gianos, E., Goldberg, I. J., & Schwartzbard, A. Z. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.007 · Cited by 33
Bosentan therapy for pulmonary arterial hypertension
Cohen, H., Chahine, C., Hui, A., & Mukherji, R. (2004) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/61.11.1107 · Cited by 36
Cardiovascular autonomic dysregulation in users of MDMA ("Ecstasy")
Brody, S., Krause, C., Veit, R., & Rau, H. (1998) · Psychopharmacology · doi:10.1007/s002130050582 · Cited by 33
“However, the present results are intriguing, and potentially of clinical importance given the recent reports of cardiac damage and pulmonary hypertension in users of fenßuramine (Connolly et al. 1997).”
ResultIbarrola, J., García-Peña, A., Matilla, L., Bonnard, B., Sádaba, R., Arrieta, V., Álvarez, V., Fernández‐Celis, A., Gainza, A., Navarro, A., et al. (2020) · Circulation Research · doi:10.1161/circresaha.119.316427 · Cited by 32
Current and future pharmacotherapy options for drug-resistant epilepsy
Elkommos, S., & Mula, M. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2128670 · Cited by 36
Factitious thyrotoxicosis and herbal dietary supplement for weight reduction
Poon, W., Ng, S. W., Lai, C.-K., Chan, Y.-W., & Mak, W. L. (2008) · Clinical Toxicology · doi:10.1080/15563650701381179 · Cited by 32
Modern Medical Management of Obesity
Aronne, L. J. (1998) · Journal of the American Dietetic Association · doi:10.1016/s0002-8223(98)00706-8 · Cited by 32
The Effects of Drugs Used to Treat Obesity on the Autonomic Nervous System
Hirsch, J., Mackintosh, R. M., & Aronne, L. J. (2000) · Obesity Research · doi:10.1038/oby.2000.26 · Cited by 32
Drug Insight: appetite suppressants
Bray, G. A. (2005) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0092 · Cited by 35
Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study
Palmieri, V., Arnett, D. K., Roman, M. J., Liu, J. E., Bella, J. N., Oberman, A., Kitzman, D. W., Hopkins, P. N., Morgan, D., SIMONE, G. D., et al. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01123-3 · Cited by 32
Endocardial Fibrosis Associated with Fenfluramine–Phentermine
Fowles, R. E., Cloward, T. V., & Yowell, R. L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804303381816 · Cited by 32
Use of Sibutramine and Other Noradrenergic and Serotonergic Drugs in the Management of Obesity
Ryan, D. H. (2000) · Endocrine · doi:10.1385/endo:13:2:193 · Cited by 32
Metadata
- Authors
- Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V.
- Affiliations
- Mayo Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1997-08-28
- Volume
- 337
- Issue
- 9
- Pages
- 581-588
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2134362869
- Cited by
- 1,632
- References
- 14
- Citations by year
- 2026: 23 · 2025: 23 · 2024: 26 · 2023: 43 · 2022: 32 · 2021: 40 · 2020: 35 · 2019: 39 · 2018: 42 · 2017: 55 · 2016: 54 · 2015: 58 · 2014: 51 · 2013: 55 · 2012: 59
- FWCI
- 72.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Issues in Pregnancy
- Keywords
- valvular heart disease, pulmonary hypertension, anorectic agents, women, adverse drug reactions
- MeSH terms
- Adult, Aortic Valve Insufficiency, Appetite Depressants, Drug Combinations, Female, Fenfluramine, Heart Valve Diseases, Humans, Hypertension, Pulmonary, Middle Aged, Mitral Valve, Mitral Valve Insufficiency, Phentermine, Tricuspid Valve Insufficiency, Ultrasonography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.